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Although there is evidence for correlations between disability and magnetic resonance
imaging (MRI) total lesion volume in autosomal dominant arteriopathy with sub-
cortical infarcts and leukoencephalopathy (CADASIL), the significance of structural
MRI abnormalities for cognitive dysfunction remains controversial. We performed
detailed neuropsychological testing, high resolution MRI, and Tc-99m-ethyl cystei-
nate-dimer SPECT in three CADASIL patients. MR-images were rated independently
by two investigators for the presence of white matter lesions, lacunar infarcts,
microbleeds, and ventricular enlargement. Cortical atrophy was quantified by the use
of automatic morphometric assessment of the cortical thickness. In addition, labor-
atory and patients history data were collected in order to assess the individual vas-
cular risk factor profile. The differences in cognitive performance between the three
patients are neither explained by structural-, or functional neuroimaging, nor by the
patient-specific vascular risk factor profiles. The neuroradiologically least affected
patient met criteria for dementia, whereas the most severely affected patient was in the
best clinical and cognitive state. Conventional structural and functional neuroimaging
is important for the diagnosis of CADASIL, but it is no sufficient surrogate marker for
the associated cognitive decline. Detailed neuropsychological assessment seems to be
more useful, particularly with respect to the implementation of reliable outcome
parameters in possible therapeutic trials.
Introduction
Cerebral autosomal dominant arteriopathy with sub-
cortical infarcts and leukoencephalopathy (CADASIL)
is an inherited vasculopathy of small arteries and arte-
rioles of the brain and other organs. The disorder is
caused by a mutation in the transmembrane receptor
product of the Notch3 gene at chromosome 19 [1,2]. In
the third decade, almost all gene carriers show patho-
logic findings on magnetic resonance imaging (MRI).
Different from other types of cerebral small vessel dis-
ease (CSVD) [3] white matter lesions (WMLs) often
affect the temporopolar white matter and the subcor-
tical temporopolar and superior frontal U-fiber-system
[4,5].
The specific relationships between MRI abnormalit-
ies and cognitive state are neither clear in CADASIL
nor in CSVD in general [6–9]. Several recent studies
reported correlations between MRI- and clinical find-
ings in CADASIL, both for conventional [10,11] and
advanced imaging techniques [12,13]. However, the
results remain controversial [14,15] and correlations
seem to be weak at best. It furthermore has been
speculated that in the absence of strong genotype–
phenotype relationships [16,17] the specific phenotype
in CADASIL patients might be influenced by gene–
environment interactions, and in particular by con-
ventional cardiovascular risk factors [18,19].
We investigated a kindred of three newly diagnosed
CADASIL patients with a variety of neuropsychologi-
cal, neuroimaging, and laboratory tools, which is not
easily feasible in large patient populations. The aim of
our study was to further evaluate the potential of both
neuroimaging and laboratory data to serve as surrogate
markers, focusing on cognitive state.
Patient descriptions
Patient I is a 41-year-old right-handed male with a
history of recurring TIAs (pure sensory, pure motor,
sensory-motor) since 1995. There is no history of
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migraine, but the patient has suffered from bilateral
sensorineural hearing loss since childhood. Since the
middle of 1999 progressive memory loss and behavioral
changes have been reported. Eventually, after a first
epileptic seizure in February 2001 the patient was
continuously unfit for work. Neurological examinations
in April 2001 and November 2003 showed a slight right
hemiparesis and a mild dysarthria. Extracranial/trans-
cranial Doppler/Duplex-ultrasound (CCS/TCCS) and
echocardiography were normal. Twenty-four-hour
blood pressure-monitoring results were unremarkable.
Genetic testing (Professor E. Tournier Lasserve,
Hopital Lariboisiere, Paris, France) revealed a Notch3
mutation (C622T) in exon 4, leading to the amino acid
change R182C.
Patient II, the mother of patient I, is a 65-year-old
right-handed woman who also has a history of bilat-
eral sensorineural hearing loss. In June 1993 she
suffered the first stroke with a right-sided hemiparesis,
which resolved completely. In October 1997 the
patient developed a subacute right-sided hemiparesis.
Anticoagulation with phenprocoumon was started.
Neurological examinations in January and November
2003 showed only a mild right hemiparesis. The patient
was independent in all activities of daily living. CCS/
TCCS, echocardiography, and 24-h blood pressure
monitoring results were unremarkable. Genetic testing
revealed the same Notch3 mutation as in patient I.
Patient III is a 53-year-old right-handed man, and
is a great-cousin of patient I. The patient has a his-
tory of progressive bilateral senorineural hearing loss
of childhood onset, too. In addition, the patient was
under medical supervision for mild arterial hyperten-
sion and hypercholesterolemia, which was treated
with simvastatin. In August 2004 there was a first
transient monoparesis of the left lower limb. Anti-
platelet agents (dipyridamole, aspirin) and enalapril
were prescribed. Neurological examination in
November 2004 was normal. The patient was inde-
pendent in all activities of daily living, and he was
able to do his job as electrical engineer. CCS/TCCS
and echocardiography findings were normal. Twenty-
four-hour blood pressure monitoring showed mar-
ginally elevated diastolic blood pressures. Genetic




Magnetic resonance imaging was performed on a 3Te-
sla whole body system (Medspec 3T/100; Bruker, Ettl-
ingen, Germany, or Magnetom TRIO; Siemens,
Erlangen, Germany). The imaging protocol consisted of
four scans of the same geometry (20 slices, axial and
coronal planes, slice thickness 2 mm, slice gap 2.5 mm):
(i) 2D T1-weighted reduced power multislice modified
driven equilibrium Fourier transform (MDEFT)-ima-
ges [20]. (ii) 2D T2-weighted fast spin-echo (FSE) scans.
(iii) 3D T1-weighted MDEFT-images. (iv) 2D T2*-
weighted gradient echo images.
Because of the lack of commonly agreed concepts
regarding the use of MRI rating scales of WMLs and
CSVD [21] a recently proposed rating scale, which is an
extension of the scale of van Swieten [22] was used for
grading of the MRI lesions [23]. Extent and site of
diffuse WMLs were assessed separately, the semiquan-
titative rating scale ranging from absent ¼ 0, to
severe ¼ 3. In addition, all sharply demarcated lesions
isointense to CSF on the T1- and T2-weighted images
suggesting lacunar infarcts (LIs) were registered on each
slice according to their anatomical location. The total
number and site of LIs was calculated separately for the
three patients. The same procedure was performed for
circumscribed hypointense lesions on the T2*-images,
representing cerebral microbleeds (MBs) [24,25]. All
MR-images were evaluated independently by two neu-
roradiologically experienced readers (RS, CP), and the
coefficient of agreement (j) was calculated [26]. The
width of the third ventricle was used to estimate major
inner brain atrophy. An automated segmentation
algorithm for the assessment of the cortical thickness
was applied to quantify overall cortical atrophy [27].
SPECT
Patients were injected i.v. with 600 MBq Tc-99m-ethyl
cysteinate-dimer (ECD) under standard resting condi-
tions. SPECT acquisition with a brain dedicated gam-
ma camera (Ceraspect, DSI, Waltham, MA, USA) was
started 30 min post-injection. Photons were registered
in a 128 · 128 · 64 matrix during 30 min. Datasets
were reconstructed by filtered backprojection. SPECT
study analysis was performed with the software BRASS
(Nuclear Diagnostics, Stockholm, Sweden). Ratios of
mean count rates in pre-defined three-dimensional
volumes of interest (VOIs) to mean cerebellar counts
were calculated for 16 brain regions covering major
cortical and subcortical gray matter structures. Because
visual analysis did not reveal significant asymmetries or
bilateral reductions of cerebellar tracer uptake, the
application of the cerebellum as reference region was
considered reasonable. Furthermore individual patient
SPECT studies were automatically compared to a mean
count template of non-pathological Tc-99m-ECD
SPECT scans of 23 adults (14 females, 9 males, mean
age 47 ± 16 years).
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Neuropsychological evaluation
A comprehensive battery of neuropsychological tests
was administered in order to assess verbal intelligence,
attention, declarative memory and learning, as well as
executive functions.
Vascular risk factor profile
Data from patient’s histories and laboratory tests were




Table 1 summarizes the results of the MRI rating
procedure. Agreement in rating was good (j ¼ 0.6).
All three patients reached a maximum grade of
CSVD. All major lobes and both hemispheres were
affected, with preference of the frontal and parietal
lobes, and the deep white matter. LIs were detected
with nearly the same frequency in patients I and
II (7.5 vs. 8) but their number was substantially
increased in patient III (23.5). T2* GE-imaging
revealed MBs in the subcortical white matter in all
three patients. However, in patient I only a single MB
was detected, whereas 9 MBs were present in patient
II, and 13.5 in patient III. Infarcts suggesting large
vessel disease or embolism were absent in all patients.
The width of the third ventricle was identical in the
three patients and was within normal limits. Overall
cortical thickness (patient I: 3.28 mm left hemisphere,
3.27 mm right hemisphere; patient II: 3.3 mm left
hemisphere, 3.5 mm right hemisphere; patient III
3.09 mm left hemisphere, 3.08 mm right hemisphere)
did not differ from values obtained in 27 healthy
individuals of different age groups [28].
Table 1 Mean rating scores of severity and localization of diffuse
white matter lesions (DWMLs), mean numbers and specific site of
lacunar infarcts (LIs), and mean numbers and site of microbleeds
(MBs), as was assessed separately by two investigators
Patient I Patient II Patient III
DWMLs
fl 3 3 3
pl 3 3 3
tl 1.5 2.5 2.5
ol 2 2 2
pv 1.5 2.5 3
Mean 2.4 2.6 2.7
Lacunes
pv 1 0 4
ci 0 1 2
cr 2 0.5 2
bg 2 1 4.5
th 0 1 2.5
bs 2 0 3
scwm 0 0.5 1.5
dwm 0.5 3.5 3
Other 0 0.5 1
Total 7.5 8 23.5
MBs
fl 0 0.5 0
pl 0 3 0
tl 1 1 1.5
ol 0 0.5 1
cb 0 3 3
th 0 0 4
bg 0 0 2
pv 0 0 1
dwm 0 0 0
bs 0 1 1
Other 0 0 0
Total 1 9 13.5
Third ventricle (mm) 8 8 8
DWMLs according to a simple 3-point scale (1 ¼ mild, 2 ¼ moderate,
3 ¼ severe). Width of the third ventricle (mm) as a parameter for
overall inner brain atrophy.
bg, basal ganglia; bs, brain stem; cb, cerebellum; ci, capsula interna; cr,
corona radiata; dwm, deep white matter; fl, frontal lobe; ol, occipital
lobe; pl, parietal lobe; pv, perinventricular white matter; scwm,
subcortical white matter; tl, temporal lobe; th, thalamus.
Table 2 Summary of the applied neuropsychological tests and
patient’s performance
Neuropsychological tests Patient I Patient II Patient III
Years of education 10 8 10
MWT-B (IQ) 93 95 112
TAP-alertness/median (PR) 1 5 93
TAP-alertness/SD (PR) 1 16 58








Verbal memory (index) 92 70 82








MCST/categories 4 4 5
MCST/perseverative errors 18/11 11/2 13/2
BADS, behavioural assessment of the dysexecutive syndrome;
MCST, modified card sorting test; MWT-B, Mehrfachwahlworts-
chatztest; PR, percentile; SD, standard deviation; TAP, Testbatterie
zur Aufmerksamkeitspru¨fung; WMS-R, Wechsler Memory
Scale-revised.
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SPECT
All three patients showed a reduced regional cerebral
blood flow (rCBF) in the cingulate cortex. Patient I
showed decreased rCBF particularly in the temporal
cortices of both hemispheres, whereas in patient II
additional defects were found in the thalamic and
fronto-parietal cortices. Patient III showed the most
marked rCBF-reduction of all patients, and in partic-
ular the subcortical gray matter and the parietal cortices
were affected.
Neuropsychological testing
Table 2 summarizes the test performance of the
patients. Premorbid intelligence was average in the
three patients. Simple (visual) reaction times [29] were
normal in patient III, and only mildly impaired in
patient II, whereas patient I showed a severe slowing
of information processing and a large variability of
responses. In a Stroop-Task [30], interference was high
only in patient I. Capacity of short-term memory was
reduced in patients I and II. The memory quotient [31]
was slightly reduced in all patients, but only patient I
showed fast forgetting. Age-corrected standard scores
of the Behavioural assessment of the dysexecutive syn-
drome (BADS) [32] were borderline in patients I and II,
and normal in patient III. In a modified cardsorting test
[33] patient I made many perseverative errors.
Laboratory tests, vascular risk factors
Patients I and III had hypercholesterolemia and hom-
ocysteinemia. Patient I was obese (BMI 33 kg/m2) and
R R R
Figure 1 Comparison of T2-weighted MR-images of patient I (left), patient II (middle), and patient III (right). Upper row: axial images at
the level of the basal ganglia. Lower row: axial images at the level of the centrum semiovale. Confluent white matter lesions (WMLs) as
well as lacunar infarcts are most pronounced in patient III. Note the marked involvement of the frontal white matter and the extension of
the WMLs into the subcortical U-fibers in this patient.
366 R. Scheid et al.
 2006 EFNS European Journal of Neurology 13, 363–370
had a history of tobacco abuse (20 pack years). Patient
II was heterozygous for the factor V-Leiden mutation.
Patient III had a history of arterial hypertension and
hyperfibrinogenemia.
Discussion
The main result of our study is a relative mismatch
between neuroimaging findings and cognitive state.
MRI depicted severe abnormalities in all three patients
(Fig. 1). However, as was documented by the evalua-
tion process of the MR-images by two independent
readers, semiquantitative measurements of specific fea-
tures (DWMLs, LIs, MBs) revealed substantial differ-
ences. The best cognitive performance was documented
in the structurally most severely affected individual, and
vice versa. Age differences are not responsible for this
discrepancy. These should influence cognition in the
    R         L
(a)
   (b)
(c)
Figure 2 Parametric images of rCBF-SPECT studies of patient I (a), II (b) and III (c). Axial slices show regional cerebral blood flow
(rCBF)-reduction as pixelwise colorcoded z-scores (number of standard deviations from mean) resulting from an automated comparison
of the individual SPECT studies with a normal template (software BRASS). Areas of significantly reduced rCBF are colored in red.
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same direction, and not the other way round, as is the
case in our patients, in whom the youngest fulfilled
DSM-IV criteria of dementia [34].
Knowing about the limitations of studies with single
subjects or small samples [35], our results qualify the
results of several previously published studies concern-
ing the correlation of MRI- and clinical findings in
CADASIL [10,11,36]. The discrepancies may partly be
explained by the insufficient sensitivity of the instru-
ments used for the assessment of function. Scores like
the Rankin scale [37], the EDSS score [38], or the
Barthel Index [39] are determined mainly by motor
functioning and are fairly rough. E.g. all three of our
patients reached a score of 100 in the Barthel index and
a score of 1 in the Rankin scale. The same applies to
instruments for the evaluation of cognitive functioning
like the MMSE or SIDAM [40,41]. A further explan-
ation results from the limited validity of current MRI-
morphometry [42].
Measurements of ventricular enlargement, as well as
regional and overall cortical thickness were not helpful
in our study. The latter finding may indicate that cor-
tical hypometabolism could indeed be caused by remote
effects because of functional disruption of subcortical
fibers in CADASIL, and may not be a result of cortical
atrophy itself [43]. However, in our patients, rCBF
determined by SPECT did not correlate with cognitive
performance, either. Patient III showed the most severe
rCBF-reduction in 16/16 examined VOIs (Fig. 2).
Nuclear medicine techniques have not often been used
in the evaluation of CADASIL, and findings concern-
ing the relationship between CBF and WMLs are
inconsistent [43–47]. Our observations support the
assumption of a positive correlation, but likewise indi-
cate that neither CBF-measurement nor structural MRI
are sufficient functional surrogate markers. In partic-
ular, our observations are contrary to the results of a
previous study by one of the authors on subjects with
CSVD [7]. Differences between the etiopathogenetic
mechanisms underlying the cognitive decline in
CADASIL and unspecified CSVD could therefore be
hypothesized. However, further studies with more
patients are necessary on that score.
It seems probably that CADASIL primarily
restricts cognition [14,48–50]. As long as there are no
imaging procedures, which are more sensitive for
subtle functional impairments, detailed neuropsycho-
logical testing may be the best instrument for the
assessment of disease severity and progression. This is
particularly important in early stages and for the
evaluation of potential preventive therapies in
CADASIL. However, as recent studies suggest that
the measurement of water diffusion over time could
be a useful marker for the progression of tissue
damage, the role of diffusion tensor imaging needs to
be examined further in this respect [12,13].
The vascular risk factor profiles of our patients are
heterogeneous and specific interrelations regarding
cognition are not to be assumed. Noteworthy, the
clinically most affected patient was the only one with
a history of smoking. Smoking has been reported to
be correlated with onset of stroke/transient ischemic
attack [19]. It therefore could be speculated that
tobacco abuse might have a particular negative
pharmacodynamic effect in CADASIL.
An additional interesting, but with respect to the aim
of our study not further considered finding is the sen-
sorineural hearing loss of which all three patients were
suffering from. Hearing loss has repeatedly been
reported in CADASIL patients [16,51–53]. However,
there is no information about its etiology and signifi-
cance. Further studies are therefore needed to clarify if
neurosensory hearing loss might not only be associated
but might be caused by CADASIL, and if it could be an
early clinical marker of the disease.
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